Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Physical Sciences, Biochemistry & Molecular Biology, Chemistry, Multidisciplinary, Chemistry, calcium ATPase, cardiac muscle, acetyltransferase, post-translational modifications, SARCOPLASMIC-RETICULUM CA2+-ATPASE, HISTONE ACETYLTRANSFERASE ACTIVITY, GENE-TRANSFER, HEART-FAILURE, P300, TRANSCRIPTION, EXPRESSION, MODEL, PHOSPHOLAMBAN, CONTRACTILITY, Humans, Heart Failure, Lysine, Myocytes, Cardiac, p300-CBP Transcription Factors, Protein Processing, Post-Translational, Sarcoplasmic Reticulum Calcium-Transporting ATPases, 0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences, Chemical Physics, 3101 Biochemistry and cell biology, 3107 Microbiology, 3404 Medicinal and biomolecular chemistry

Abstract:

Impaired calcium uptake resulting from reduced expression and activity of the cardiac sarco-endoplasmic reticulum Ca2+ ATPase (SERCA2a) is a hallmark of heart failure (HF). Recently, new mechanisms of SERCA2a regulation, including post-translational modifications (PTMs), have emerged. Our latest analysis of SERCA2a PTMs has identified lysine acetylation as another PTM which might play a significant role in regulating SERCA2a activity. SERCA2a is acetylated, and that acetylation is more prominent in failing human hearts. In this study, we confirmed that p300 interacts with and acetylates SERCA2a in cardiac tissues. Several lysine residues in SERCA2a modulated by p300 were identified using in vitro acetylation assay. Analysis of in vitro acetylated SERCA2a revealed several lysine residues in SERCA2a susceptible to acetylation by p300. Among them, SERCA2a Lys514 (K514) was confirmed to be essential for SERCA2a activity and stability using an acetylated mimicking mutant. Finally, the reintroduction of an acetyl-mimicking mutant of SERCA2a (K514Q) into SERCA2 knockout cardiomyocytes resulted in deteriorated cardiomyocyte function. Taken together, our data demonstrated that p300-mediated acetylation of SERCA2a is a critical PTM that decreases the pump's function and contributes to cardiac impairment in HF. SERCA2a acetylation can be targeted for therapeutic aims for the treatment of HF.